Spots Global Cancer Trial Database for frontline
Every month we try and update this database with for frontline cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | NCT01139359 | Lymphoma | darinaparsin CHOP | 18 Years - | Alaunos Therapeutics | |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | NCT01139359 | Lymphoma | darinaparsin CHOP | 18 Years - | Alaunos Therapeutics | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | NCT05551936 | Follicular Lymp... | Bendamustine Rituximab Tazemetostat | 18 Years - | Big Ten Cancer Research Consortium | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | NCT03863184 | Mantle Cell Lym... | Acalabrutinib Lenalidomide Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | NCT05551936 | Follicular Lymp... | Bendamustine Rituximab Tazemetostat | 18 Years - | Big Ten Cancer Research Consortium | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
